Single Subject Neratinib in Bladder Cancer (NRR)

UNC Lineberger Comprehensive Cancer Center

Status

Conditions: Bladder Cancer

Treatments: Drug: Neratinib

Study type: Expanded Access

Funder types: Other

Identifiers

NCT01956253

13-2526

Details and patient eligibility

About

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

* none

Exclusion criteria

* none

We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.